免疫グロブリン市場規模、シェア、成長分析：適応症別、剤形別、投与経路別、エンドユーザー別、地域別 - 産業予測 2025～2032年

免疫グロブリン市場規模は2023年に164億米ドルと評価され、2024年の175億2,000万米ドルから2032年には296億5,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.8％で成長する見通しです。

世界の免疫グロブリン市場は、免疫疾患の罹患率の上昇と診断・治療技術の進歩に後押しされ、大幅な成長が見込まれています。規制状況やヘルスケア支出の増加が、この拡大をさらに後押ししています。技術革新と研究開発への投資拡大により、免疫グロブリン治療の質と有効性が向上しています。さらに、アジア太平洋やラテンアメリカを中心とする新興市場は、大きな成長機会を提供しています。これらの洞察は、免疫グロブリン市場の有望な見通しを示唆しており、業界利害関係者に対し、これらの重要な治療法に対する増大する需要を満たすため、技術革新を優先し、生産能力を拡大し、市場浸透戦略を模索するよう促しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 特許分析

免疫グロブリン市場規模：適応症別& CAGR（2025-2032）

• 市場概要
• 原発性免疫不全症（PI）
• 二次免疫不全症（SID）
• 慢性炎症性脱髄性多発神経炎（CIDP）
• ギランバレー症候群
• 免疫血小板減少性紫斑病（ITP）
• 多巣性運動神経障害（MMN）
• その他

免疫グロブリン市場規模：剤形別& CAGR（2025-2032）

• 市場概要
• 液体
• 凍結乾燥

免疫グロブリン市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 静脈内
• 皮下

免疫グロブリン市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• クリニック
• ホームケア
• その他

免疫グロブリン市場規模& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Grifols（Spain）
• CSL Limited（Australia）
• Octapharma（Switzerland）
• Kedrion Biopharma（Italy）
• Biotest AG（Germany）
• LFB Group（France）
• Shanghai RAAS Blood Products（China）
• China Biologic Products Holdings（China）
• Baxter International Inc.（USA）
• Takeda Pharmaceutical Company（Japan）
• Sanquin（Netherlands）
• Bio Products Laboratory（UK）
• Emergent BioSolutions（USA）
• ADMA Biologics（USA）
• Kamada Ltd.（Israel）
• Green Cross Corporation（South Korea）
• SK Plasma（South Korea）
• Hualan Biological Engineering Inc.（China）
• Beijing Tiantan Biological Products（China）
• Shire Plc（UK）

結論と提言

Immunoglobulin Market size was valued at USD 16.4 billion in 2023 and is poised to grow from USD 17.52 billion in 2024 to USD 29.65 billion by 2032, growing at a CAGR of 6.8% during the forecast period (2025-2032).

The global Immunoglobulin market is poised for considerable growth, fueled by the rising incidence of immunological disorders and advancements in diagnostic and therapeutic techniques. A supportive regulatory landscape and increasing healthcare expenditures further bolster this expansion. Innovations and heightened investment in research and development are enhancing the quality and effectiveness of Immunoglobulin therapies. Additionally, emerging markets, notably in the Asia-Pacific and Latin America regions, offer substantial opportunities for growth. These insights suggest a promising outlook for the Immunoglobulin market, encouraging industry stakeholders to prioritize innovation, scale up capacities, and explore market penetration strategies to satisfy the growing demand for these vital therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Immunoglobulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Immunoglobulin Market Segments Analysis

Global Immunoglobulin Market is segmented by Indication, Form, Route of Administration, End-User and region. Based on Indication, the market is segmented into Primary Immunodeficiency (PI), Secondary Immunodeficiency (SID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain Barre Syndrome, Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN) and Others. Based on Form, the market is segmented into Liquid and Lyophilized. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, Intramuscular. Based on End-User, the market is segmented into Hospitals, Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Immunoglobulin Market

A significant driver of the global Immunoglobulin market is the rising incidence of immunological disorders. Immunoglobulins are essential for treating a variety of conditions, including primary immunodeficiencies, autoimmune diseases, and infectious diseases. The growing prevalence of these disorders, enhanced by better diagnostic methods and increased awareness, is driving the demand for Immunoglobulin therapies. Contributing factors include genetic susceptibility, environmental influences, and lifestyle shifts that lead to a higher occurrence of immunological issues worldwide. Moreover, improvements in healthcare infrastructure, greater access to medical services, and increasing healthcare spending are also pivotal in propelling the market's expansion.

Restraints in the Immunoglobulin Market

A major constraint faced by the global Immunoglobulin market is the steep cost associated with Immunoglobulin therapies. The intricate processes required for the production, purification, and storage of these therapies contribute to elevated manufacturing expenses, which in turn lead to higher prices for patients and healthcare systems. This financial barrier is particularly pronounced in developing nations where healthcare resources are limited and affordability is a critical concern. Additionally, reimbursement challenges and restricted insurance coverage further exacerbate the financial strain on individuals seeking these therapies. Consequently, it is vital to explore strategies aimed at minimizing production costs, fostering market competition, and enhancing the availability of affordable Immunoglobulin treatments to improve patient access and care.

Market Trends of the Immunoglobulin Market

The global Immunoglobulin market is witnessing a prominent trend characterized by a surge in the adoption of intravenous immunoglobulin (IVIG) therapy. This therapy, crucial for patients with immunodeficiency disorders, autoimmune diseases, and specific neurological conditions, has gained traction due to its proven efficacy and the heightened awareness of its therapeutic benefits among healthcare professionals and patients alike. Innovations in production technologies, enhanced product safety standards, and the broadening scope of IVIG indications are fueling this adoption. Concurrently, the rising incidence of immunological disorders and an aging population are further propelling the demand for Immunoglobulin products, solidifying IVIG therapy's pivotal role in modern medicine.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Patent Analysis

Global Immunoglobulin Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Primary Immunodeficiency (PI)
• Secondary Immunodeficiency (SID)
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Guillain Barre Syndrome
• Immune Thrombocytopenic Purpura (ITP)
• Multifocal Motor Neuropathy (MMN)
• Others

Global Immunoglobulin Market Size by Form & CAGR (2025-2032)

• Market Overview
• Liquid
• Lyophilized

Global Immunoglobulin Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Intravenous
• Subcutaneous

Global Immunoglobulin Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Homecare
• Others

Global Immunoglobulin Market Size & CAGR (2025-2032)

• North America (Indication, Form, Route of Administration, End-User)
  • US
  • Canada
• Europe (Indication, Form, Route of Administration, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Indication, Form, Route of Administration, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Indication, Form, Route of Administration, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Indication, Form, Route of Administration, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Grifols (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion Biopharma (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai RAAS Blood Products (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Biologic Products Holdings (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanquin (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADMA Biologics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kamada Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SK Plasma (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hualan Biological Engineering Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beijing Tiantan Biological Products (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations